Heidi M Mansour

List of Publications by Year
in descending order

79	3,190	147801 31	155660 55
papers	citations	h-index	g-index

80	80	80	4037
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nanomedicine in pulmonary delivery. International Journal of Nanomedicine, 2009, 4, 299.	6.7	378
2	Materials for Pharmaceutical Dosage Forms: Molecular Pharmaceutics and Controlled Release Drug Delivery Aspects. International Journal of Molecular Sciences, 2010, 11, 3298-3322.	4.1	168
3	Inhalable nanoparticulate powders for respiratory delivery. Nanomedicine: Nanotechnology, Biology, and Medicine, 2015, 11, 1189-1199.	3.3	165
4	Reversion of multidrug resistance by co-encapsulation of doxorubicin and curcumin in chitosan/poly(butyl cyanoacrylate) nanoparticles. International Journal of Pharmaceutics, 2012, 426, 193-201.	5.2	163
5	Physical Characterization of Component Particles Included in Dry Powder Inhalers. I. Strategy Review and Static Characteristics. Journal of Pharmaceutical Sciences, 2007, 96, 1282-1301.	3.3	127
6	Therapeutic Liposomal Dry Powder Inhalation Aerosols for Targeted Lung Delivery. Lung, 2012, 190, 251-262.	3.3	119
7	Characterization and aerosol dispersion performance of advanced spray-dried chemotherapeutic PEGylated phospholipid particles for dry powder inhalation delivery in lung cancer. European Journal of Pharmaceutical Sciences, 2013, 49, 699-711.	4.0	89
8	Physical Characterization of Component Particles Included in Dry Powder Inhalers. II. Dynamic Characteristics. Journal of Pharmaceutical Sciences, 2007, 96, 1302-1319.	3.3	81
9	Role of Nrf2 and Autophagy in Acute Lung Injury. Current Pharmacology Reports, 2016, 2, 91-101.	3.0	77
10	Advanced spray-dried design, physicochemical characterization, and aerosol dispersion performance of vancomycin and clarithromycin multifunctional controlled release particles for targeted respiratory delivery as dry powder inhalation aerosols. International Journal of Pharmaceutics, 2013, 455, 374-392.	5.2	73
11	Formulation and characterization of inhalable magnetic nanocomposite microparticles (MnMs) for targeted pulmonary delivery via spray drying. International Journal of Pharmaceutics, 2015, 479, 320-328.	5.2	66
12	Particle Interactions in Dry Powder Inhaler Unit Processes: A Review. Journal of Adhesion Science and Technology, 2011, 25, 451-482.	2.6	65
13	Dry powder inhalers in COPD, lung inflammation and pulmonary infections. Expert Opinion on Drug Delivery, 2015, 12, 947-962.	5.0	63
14	Pulmonary Hypertension in Cystic Fibrosis with Advanced Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2014, 190, 898-905.	5.6	62
15	Relationships between Equilibrium Spreading Pressure and Phase Equilibria of Phospholipid Bilayers and Monolayers at the Airâ^'Water Interface. Langmuir, 2007, 23, 3809-3819.	3.5	59
16	Raman characterization and chemical imaging of biocolloidal self-assemblies, drug delivery systems, and pulmonary inhalation aerosols: A review. AAPS PharmSciTech, 2007, 8, 140.	3.3	57
17	Autophagy in neonatal hypoxia ischemic brain is associated with oxidative stress. Redox Biology, 2015, 6, 516-523.	9.0	57
18	Inhalable PEGylated Phospholipid Nanocarriers and PEGylated Therapeutics for Respiratory Delivery as Aerosolized Colloidal Dispersions and Dry Powder Inhalers. Pharmaceutics, 2014, 6, 333-353.	4.5	52

#	Article	IF	Citations
19	Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection. Pharmaceutics, 2021, 13, 1077.	4.5	50
20	Design, physicochemical characterization, and optimization of organic solution advanced spray-dried inhalable dipalmitoylphosphatidylcholine (DPPC) and dipalmitoylphosphatidylethanolamine poly(ethylene glycol) (DPPE-PEG) microparticles and nanoparticles for targeted respiratory nanomedicine delivery as dry powder inhalation aerosols. International Journal of Nanomedicine, 2013, 8, 275.	6.7	48
21	Influence of Pulmonary Hypertension on Patients With Idiopathic Pulmonary Fibrosis Awaiting Lung Transplantation. Annals of Thoracic Surgery, 2016, 101, 246-252.	1.3	47
22	Comparison of Bilayer and Monolayer Properties of Phospholipid Systems Containing Dipalmitoylphosphatidylglycerol and Dipalmitoylphosphatidylinositol. Langmuir, 2001, 17, 6622-6632.	3.5	45
23	Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried microparticulate/nanoparticulate antibiotic dry powders of tobramycin and azithromycin for pulmonary inhalation aerosol delivery. European Journal of Pharmaceutical Sciences, 2014, 52, 191-205.	4.0	45
24	Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Spray-Dried Microparticulate/Nanoparticulate Mannitol Powders for Targeted Pulmonary Delivery as Dry Powder Inhalers. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2014, 27, 81-93.	1.4	44
25	High-Performing Dry Powder Inhalers of Paclitaxel DPPC/DPPG Lung Surfactant-Mimic Multifunctional Particles in Lung Cancer: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. AAPS PharmSciTech, 2014, 15, 1574-1587.	3.3	43
26	Microparticulate/nanoparticulate powders of a novel Nrf2 activator and an aerosol performance enhancer for pulmonary delivery targeting the lung Nrf2/Keap-1 pathway. Molecular Systems Design and Engineering, 2016, 1, 48-65.	3.4	41
27	The relationship between water vapor absorption and desorption by phospholipids and bilayer phase transitions. Journal of Pharmaceutical Sciences, 2007, 96, 377-396.	3.3	40
28	Dry Powder Aerosols Generated by Standardized Entrainment Tubes From Drug Blends With Lactose Monohydrate: 2. Ipratropium Bromide Monohydrate and Fluticasone Propionate. Journal of Pharmaceutical Sciences, 2010, 99, 3415-3429.	3.3	35
29	Influence of chitosan type on the properties of extruded pellets with low amount of microcrystalline cellulose. AAPS PharmSciTech, 2007, 8, E99-E109.	3.3	34
30	Physicochemical Characterization and Water Vapor Sorption of Organic Solution Advanced Spray-Dried Inhalable Trehalose Microparticles and Nanoparticles for Targeted Dry Powder Pulmonary Inhalation Delivery. AAPS PharmSciTech, 2011, 12, 1420-1430.	3.3	34
31	Sustained-Release Delivery of Octreotide from Biodegradable Polymeric Microspheres. AAPS PharmSciTech, 2011, 12, 1293-1301.	3.3	32
32	Development of three-dimensional lung multicellular spheroids in air- and liquid-interface culture for the evaluation of anticancer therapeutics. International Journal of Oncology, 2016, 48, 1701-1709.	3.3	32
33	Dry Powder Aerosols Generated by Standardized Entrainment Tubes from Alternative Sugar Blends: 3. Trehalose Dihydrate and d-Mannitol Carriers. Journal of Pharmaceutical Sciences, 2010, 99, 3430-3441.	3.3	31
34	Phase behavior of itraconazoleâ€“phenol mixtures and its pharmaceutical applications. International Journal of Pharmaceutics, 2012, 436, 652-658.	5.2	31
35	Dry Powder Aerosols Generated by Standardized Entrainment Tubes From Drug Blends With Lactose Monohydrate: 1. Albuterol Sulfate and Disodium Cromoglycate. Journal of Pharmaceutical Sciences, 2010, 99, 3398-3414.	3.3	30
36	Advances in microscopy and complementary imaging techniques to assess the fate of drugs ex vivo in respiratory drug delivery. Advanced Drug Delivery Reviews, 2012, 64, 344-356.	13.7	30

#	Article	IF	Citations
37	Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation. Drug Design, Development and Therapy, 2013, 7, 59.	4.3	30
38	Design, Characterization, and Aerosol Dispersion Performance Modeling of Advanced Co-Spray Dried Antibiotics with Mannitol as Respirable Microparticles/Nanoparticles for Targeted Pulmonary Delivery as Dry Powder Inhalers. Journal of Pharmaceutical Sciences, 2014, 103, 2937-2949.	3.3	29
39	Design, characterization, and aerosolization of organic solution advanced spray-dried moxifloxacin and ofloxacin dipalmitoylphosphatidylcholine (DPPC) microparticulate/nanoparticulate powders for pulmonary inhalation aerosol delivery. International Journal of Nanomedicine, 2013, 8, 3489.	6.7	28
40	Prevalence of Pulmonary Hypertension and its Influence on Survival in Patients With Advanced Chronic Obstructive Pulmonary Disease Prior to Lung Transplantation. COPD: Journal of Chronic Obstructive Pulmonary Disease, 2016, 13, 50-56.	1.6	27
41	Urgent Appeal from International Society for Aerosols in Medicine (ISAM) During COVID-19: Clinical Decision Makers and Governmental Agencies Should Consider the Inhaled Route of Administration: A Statement from the ISAM Regulatory and Standardization Issues Networking Group. Journal of Aerosol Medicine and Pulmonary Drug Delivery, 2020, 33, 235-238.	1.4	27
42	Heterogeneous Particle Deaggregation and Its Implication for Therapeutic Aerosol Performance. Journal of Pharmaceutical Sciences, 2010, 99, 3442-3461.	3.3	26
43	Nanopharmaceuticals I: nanocarrier systems in drug delivery. International Journal of Nanotechnology, 2011, 8, 84.	0.2	26
44	Physicochemical characterization and aerosol dispersion performance of organic solution advanced spray-dried cyclosporine A multifunctional particles for dry powder inhalation aerosol delivery. International Journal of Nanomedicine, 2013, 8, 1269.	6.7	26
45	Surface Analytical Techniques in Solid-State Particle Characterization for Predicting Performance in Dry Powder Inhalers. KONA Powder and Particle Journal, 2010, 28, 3-19.	1.7	25
46	Spray-Dried Inhalable Powder Formulations of Therapeutic Proteins and Peptides. AAPS PharmSciTech, 2021, 22, 185.	3.3	24
47	Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 707-713.e2.	0.8	23
48	Advanced spray dried proliposomes of amphotericin B lung surfactant-mimic phospholipid microparticles/nanoparticles as dry powder inhalers for targeted pulmonary drug delivery. Pulmonary Pharmacology and Therapeutics, 2020, 64, 101975.	2.6	21
49	Nanopharmaceuticals II: application of nanoparticles and nanocarrier systems in pharmaceutics and nanomedicine. International Journal of Nanotechnology, 2011, 8, 115.	0.2	18
50	In Vitro Pulmonary Cell Culture in Pharmaceutical Inhalation Aerosol Delivery: 2-D, 3-D, and In Situ Bioimpactor Models. Current Pharmaceutical Design, 2016, 22, 2522-2531.	1.9	17
51	Pulmonary Artery Pressure and Benefit of Lung Transplantation in Adult Cystic Fibrosis Patients. Annals of Thoracic Surgery, 2016, 101, 1104-1109.	1.3	16
52	Transfusion with packed red blood cells while awaiting lung transplantation is associated with reduced survival after lung transplantation. Clinical Transplantation, 2016, 30, 1545-1551.	1.6	15
53	Inhalable Nanoparticles/Microparticles of an AMPK and Nrf2 Activator for Targeted Pulmonary Drug Delivery as Dry Powder Inhalers. AAPS Journal, 2021, 23, 2.	4.4	14
54	Characterization of the In Situ Structural and Interfacial Properties of the Cationic Hydrophobic Heteropolypeptide, KL₄, in Lung Surfactant Bilayer and Monolayer Models at the Airâ"Water Interface: Implications for Pulmonary Surfactant Delivery. Molecular Pharmaceutics, 2008, 5, 681-695.	4.6	13

#	Article	IF	Citations
55	Formoterol PLGA-PEG Nanoparticles Induce Mitochondrial Biogenesis in Renal Proximal Tubules. AAPS Journal, 2021, 23, 88.	4.4	13
56	To treat or not to treat: CFTR modulators after lung transplantation. Pediatric Transplantation, 2021, 25, e14007.	1.0	12
57	Formulation Challenges of Powders for the Delivery of Small Molecular Weight Molecules as Aerosols. , 2008, , 573-601.		12
58	Pulmonary and Nasal Anti-Inflammatory and Anti-Allergy Inhalation Aerosol Delivery Systems. Anti-Inflammatory and Anti-Allergy Agents in Medicinal Chemistry, 2011, 10, 215-229.	1.1	11
59	Advanced design and development of nanoparticle/microparticle dual-drug combination lactose carrier-free dry powder inhalation aerosols. RSC Advances, 2020, 10, 41846-41856.	3.6	11
60	Influence of Pulmonary Hypertension on Survival in Advanced Lung Disease. Lung, 2015, 193, 213-221.	3.3	10
61	Synthesis, Physicochemical Characterization, In Vitro 2D/3D Human Cell Culture, and In Vitro Aerosol Dispersion Performance of Advanced Spray Dried and Co-Spray Dried Angiotensin (1â€”7) Peptide and PNA5 with Trehalose as Microparticles/Nanoparticles for Targeted Respiratory Delivery as Dry Powder Inhalers. Pharmaceutics, 2021, 13, 1278.	4.5	9
62	Organic Solution Advanced Spray-Dried Microparticulate/Nanoparticulate Dry Powders of Lactomorphin for Respiratory Delivery: Physicochemical Characterization, In Vitro Aerosol Dispersion, and Cellular Studies. Pharmaceutics, 2021, 13, 26.	4.5	9
63	Kidney targeting of formoterol containing polymeric nanoparticles improves recovery from ischemia reperfusion-induced acute kidney injury in mice. Kidney International, 2022, 102, 1073-1089.	5.2	8
64	Improved Outcomes of Patients with End-stage Cystic Fibrosis Requiring Invasive Mechanical Ventilation for Acute Respiratory Failure. Lung, 2011, 189, 409-15.	3.3	7
65	Design and Comprehensive Characterization of Tetramethylpyrazine (TMP) for Targeted Lung Delivery as Inhalation Aerosols in Pulmonary Hypertension (PH): In Vitro Human Lung Cell Culture and In Vivo Efficacy. Antioxidants, 2021, 10, 427.	5.1	7
66	Neurofilament light: a possible prognostic biomarker for treatment of vascular contributions to cognitive impairment and dementia. Journal of Neuroinflammation, 2021, 18, 236.	7.2	7
67	Inhaled medical aerosols by nebulizer delivery in pulmonary hypertension. Pulmonary Circulation, 2018, 8, 1-2.	1.7	6
68	Advanced therapeutic inhalation aerosols of a Nrf2 activator and RhoA/Rho kinase (ROCK) inhibitor for targeted pulmonary drug delivery in pulmonary hypertension: design, characterization, aerosolization, in vitro 2D/3D human lung cell cultures, and in vivo efficacy. Therapeutic Advances in Respiratory Disease, 2021, 15, 175346662199824.	2.6	6
69	Design, Development, Physicochemical Characterization, and In Vitro Drug Release of Formoterol PEGylated PLGA Polymeric Nanoparticles. Pharmaceutics, 2022, 14, 638.	4.5	6
70	Therapeutic Cancer Vaccinesâ€”Antigen Discovery and Adjuvant Delivery Platforms. Pharmaceutics, 2022, 14, 1448.	4.5	6
71	Design and development of innovative microparticulate/nanoparticulate inhalable dry powders of a novel synthetic trifluorinated chalcone derivative and Nrf2 agonist. Scientific Reports, 2020, 10, 19771.	3.3	4
72	Comparison of l-Carnitine and l-Carnitine HCL salt for targeted lung treatment of pulmonary hypertension (PH) as inhalation aerosols: Design, comprehensive characterization, in vitro 2D/3D cell cultures, and in vivo MCT-Rat model of PH. Pulmonary Pharmacology and Therapeutics, 2020, 65, 101998.	2.6	4

#	Article	IF	Citations
73	Angiotensin-(1â€“7) Peptide Hormone Reduces Inflammation and Pathogen Burden during Mycoplasma pneumoniae Infection in Mice. Pharmaceutics, 2021, 13, 1614.	4.5	4
74	Design, Physicochemical Characterization, and In Vitro Permeation of Innovative Resatorvid Topical Formulations for Targeted Skin Drug Delivery. Pharmaceutics, 2022, 14, 700.	4.5	4
75	Advanced Microparticulate/Nanoparticulate Respirable Dry Powders of a Selective RhoA/Rho Kinase (Rock) Inhibitor for Targeted Pulmonary Inhalation Aerosol Delivery. Pharmaceutics, 2021, 13, 2188.	4.5	4
76	Glycosylated Ang-(1-7) MasR Agonist Peptide Poly Lactic-co-Glycolic Acid (PLGA) Nanoparticles and Microparticles in Cognitive Impairment: Design, Particle Preparation, Physicochemical Characterization, and In Vitro Release. Pharmaceutics, 2022, 14, 587.	4.5	3
77	Synthesis of alamandine glycoside analogs as new drug candidates to antagonize the MrgD receptor for pain relief. Medicinal Chemistry Research, 2022, 31, 1135-1146.	2.4	3
78	Therapeutics in pulmonary hypertension. , 2019, , 313-322.		2
79	Sigh Syndrome in Pediatric Asthma. Lung, 2019, 197, 111-112.	3.3	1